Treatment of myelodysplastic syndrome with thrombomimetic drugs.

@article{Santini2015TreatmentOM,
  title={Treatment of myelodysplastic syndrome with thrombomimetic drugs.},
  author={Valeria Santini and Pierre Fenaux},
  journal={Seminars in hematology},
  year={2015},
  volume={52 1},
  pages={38-45}
}
Myelodysplastic syndromes (MDS) are clinically, genetically, and molecularly heterogeneous neoplastic diseases characterized by ineffective hematopoiesis leading to peripheral cytopenias. The severity of cytopenias influences oucome and is considered in prognostic scoring systems; thrombocytopenia, although not the most frequently observed at disease onset… CONTINUE READING